Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA7 | P43166 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2989734 | 1.00 | TYR (0.46) | TYRPOLBCA12CA1CA2 | |
| SCHEMBL2987388 | 1.00 | TYR (0.46) | TYRPOLBCA12CA1CA2 | |
| SCHEMBL2986813 | 0.98 | TYR (0.45) | TYRPOLBCA12CA1CA2 | |
| SCHEMBL2984770 | 0.98 | TYR (0.45) | TYRPOLBCA12CA1CA2 | |
| SCHEMBL13206600 | 0.87 | TYR (0.42) | TYRCA12CA1CA2CA7 | |
| SCHEMBL2985213 | 0.87 | POLB (0.41) | POLBCA12CA1CA2CA7 | |
| SCHEMBL13206599 | 0.87 | TYR (0.42) | TYRCA12CA1CA2CA7 | |
| SCHEMBL2989944 | 0.80 | POLB (0.63) | POLBALDH1A1TSHR | |
| SCHEMBL2986678 | 0.77 | TYR (0.45) | TYRPOLB | |
| SCHEMBL15370358 | 0.76 | GAA (0.42) | POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7777073-B2 | Topical delivery system for antiaging and skin whitening agents | BIODERM RESEARCH (US) | 2010-08-17 | — | — | US | claimed |
| US-20090074691-A1 | Topical Delivery System for Antiaging and Skin Whitening Agents | BIODERM RESEARCH (US) | 2009-03-19 | — | — | US | claimed |
| US-7777073-B2 | Topical delivery system for antiaging and skin whitening agents | BIODERM RESEARCH (US) | 2010-08-17 | — | — | US | disclosed |
| US-20090074691-A1 | Topical Delivery System for Antiaging and Skin Whitening Agents | BIODERM RESEARCH (US) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090074691-A1 | Topical Delivery System for Antiaging and Skin Whitening Agents | TYR, MMP17, MMP1 | TYR 1/4885POLB 247/4885CA12 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.